178 related articles for article (PubMed ID: 23948264)
1. Pathological roles of ceramide and its metabolites in metabolic syndrome and Alzheimer's disease.
Yuyama K; Mitsutake S; Igarashi Y
Biochim Biophys Acta; 2014 May; 1841(5):793-8. PubMed ID: 23948264
[TBL] [Abstract][Full Text] [Related]
2. Network Analysis of a Comprehensive Knowledge Repository Reveals a Dual Role for Ceramide in Alzheimer's Disease.
Mizuno S; Ogishima S; Kitatani K; Kikuchi M; Tanaka H; Yaegashi N; Nakaya J
PLoS One; 2016; 11(2):e0148431. PubMed ID: 26849355
[TBL] [Abstract][Full Text] [Related]
3. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?
Katsel P; Li C; Haroutunian V
Neurochem Res; 2007; 32(4-5):845-56. PubMed ID: 17342407
[TBL] [Abstract][Full Text] [Related]
4. Involvement of Huanglian Jiedu Decoction on Microglia with Abnormal Sphingolipid Metabolism in Alzheimer's Disease.
Qi YY; Heng X; Yao ZY; Qu SY; Ge PY; Zhao X; Ni SJ; Guo R; Yang NY; Zhang QC; Zhu HX
Drug Des Devel Ther; 2022; 16():931-950. PubMed ID: 35391788
[TBL] [Abstract][Full Text] [Related]
5. Ceramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer's Disease and Other Neurodegenerative Diseases.
Custodia A; Romaus-Sanjurjo D; Aramburu-Núñez M; Álvarez-Rafael D; Vázquez-Vázquez L; Camino-Castiñeiras J; Leira Y; Pías-Peleteiro JM; Aldrey JM; Sobrino T; Ouro A
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897658
[TBL] [Abstract][Full Text] [Related]
6. Ganglioside and related-sphingolipid profiles are altered in a cellular model of Alzheimer's disease.
Noel A; Ingrand S; Barrier L
Biochimie; 2017 Jun; 137():158-164. PubMed ID: 28365364
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod Affects Transcription of Genes Encoding Enzymes of Ceramide Metabolism in Animal Model of Alzheimer's Disease.
Jęśko H; Wencel PL; Wójtowicz S; Strosznajder J; Lukiw WJ; Strosznajder RP
Mol Neurobiol; 2020 Jun; 57(6):2799-2811. PubMed ID: 32356173
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome.
Kim B; Feldman EL
Exp Mol Med; 2015 Mar; 47(3):e149. PubMed ID: 25766618
[TBL] [Abstract][Full Text] [Related]
9. Amyloid Beta-Peptide 25-35 (Aβ
Tang Z; Motoyoshi K; Honda T; Nakamura H; Murayama T
Biol Pharm Bull; 2021; 44(10):1419-1426. PubMed ID: 34602551
[TBL] [Abstract][Full Text] [Related]
10. Aberrant sphingomyelin/ceramide metabolic-induced neuronal endosomal/lysosomal dysfunction: potential pathological consequences in age-related neurodegeneration.
Soreghan B; Thomas SN; Yang AJ
Adv Drug Deliv Rev; 2003 Nov; 55(11):1515-24. PubMed ID: 14597144
[TBL] [Abstract][Full Text] [Related]
11. Ceramide synthases as potential targets for therapeutic intervention in human diseases.
Park JW; Park WJ; Futerman AH
Biochim Biophys Acta; 2014 May; 1841(5):671-81. PubMed ID: 24021978
[TBL] [Abstract][Full Text] [Related]
12. Gender-dependent accumulation of ceramides in the cerebral cortex of the APP(SL)/PS1Ki mouse model of Alzheimer's disease.
Barrier L; Ingrand S; Fauconneau B; Page G
Neurobiol Aging; 2010 Nov; 31(11):1843-53. PubMed ID: 19036474
[TBL] [Abstract][Full Text] [Related]
13. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease.
Frisardi V; Solfrizzi V; Seripa D; Capurso C; Santamato A; Sancarlo D; Vendemiale G; Pilotto A; Panza F
Ageing Res Rev; 2010 Oct; 9(4):399-417. PubMed ID: 20444434
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Modifications in Human Biofluids Suggest the Involvement of Sphingolipid, Antioxidant, and Glutamate Metabolism in Alzheimer's Disease Pathogenesis.
Ellis B; Hye A; Snowden SG
J Alzheimers Dis; 2015; 46(2):313-27. PubMed ID: 25835424
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
16. Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids.
Gatt S; Dagan A
Chem Phys Lipids; 2012 May; 165(4):462-74. PubMed ID: 22387097
[TBL] [Abstract][Full Text] [Related]
17. Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity.
Samad F; Badeanlou L; Shah C; Yang G
Adv Exp Med Biol; 2011; 721():67-86. PubMed ID: 21910083
[TBL] [Abstract][Full Text] [Related]
18. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
19. Sphingolipids: critical players in Alzheimer's disease.
van Echten-Deckert G; Walter J
Prog Lipid Res; 2012 Oct; 51(4):378-93. PubMed ID: 22835784
[TBL] [Abstract][Full Text] [Related]
20. Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets?
Mielke MM; Lyketsos CG
Neuromolecular Med; 2010 Dec; 12(4):331-40. PubMed ID: 20571935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
